$VIRX
Viracta Therapeutics, Inc.

2015 Q1 Form 10-Q Financial Statement

#000156459015003315 Filed on May 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $854.0K $1.995M
YoY Change -57.19% 0.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.110M $3.420M
YoY Change 49.42% 40.16%
% of Gross Profit
Research & Development $4.512M $7.552M
YoY Change -40.25% 2.37%
% of Gross Profit
Depreciation & Amortization $11.00K $5.000K
YoY Change 120.0% -28.57%
% of Gross Profit
Operating Expenses $9.623M $10.97M
YoY Change -12.27% 11.69%
Operating Profit -$8.769M -$8.974M
YoY Change -2.28% 14.58%
Interest Expense $239.0K $547.0K
YoY Change -56.31% -34.18%
% of Operating Profit
Other Income/Expense, Net -$120.0K -$5.052M
YoY Change -97.62% 70.62%
Pretax Income -$9.130M -$14.57M
YoY Change -37.34% 25.39%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.128M -$14.57M
YoY Change -37.36% 25.37%
Net Earnings / Revenue -1068.85% -730.48%
Basic Earnings Per Share -$0.81 -$0.26
Diluted Earnings Per Share -$0.81 -$0.26
COMMON SHARES
Basic Shares Outstanding 11.27M 56.31M
Diluted Shares Outstanding 11.27M 56.31M

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.80M $70.70M
YoY Change -43.71% 15.9%
Cash & Equivalents $18.78M $50.35M
Short-Term Investments $21.00M $20.30M
Other Short-Term Assets $1.500M $1.100M
YoY Change 36.36% -8.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $41.30M $71.76M
YoY Change -42.44% 15.36%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $41.00K
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K
YoY Change
Total Long-Term Assets $2.000K $74.00K
YoY Change -97.3% -26.0%
TOTAL ASSETS
Total Short-Term Assets $41.30M $71.76M
Total Long-Term Assets $2.000K $74.00K
Total Assets $41.30M $71.83M
YoY Change -42.5% 15.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.121M $1.011M
YoY Change 109.79% -32.6%
Accrued Expenses $6.000M $6.700M
YoY Change -10.45% -8.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $700.0K $9.300M
YoY Change -92.47% 13.41%
Total Short-Term Liabilities $15.92M $37.67M
YoY Change -57.74% 4.93%
LONG-TERM LIABILITIES
Long-Term Debt $6.900M $6.700M
YoY Change 2.99% -57.05%
Other Long-Term Liabilities $1.700M $1.700M
YoY Change 0.0% -82.47%
Total Long-Term Liabilities $8.600M $8.400M
YoY Change 2.38% -66.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.92M $37.67M
Total Long-Term Liabilities $8.600M $8.400M
Total Liabilities $24.50M $46.10M
YoY Change -46.85% -24.67%
SHAREHOLDERS EQUITY
Retained Earnings -$531.8M -$494.3M
YoY Change 7.6%
Common Stock $548.6M $520.0M
YoY Change 5.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.79M $25.76M
YoY Change
Total Liabilities & Shareholders Equity $41.30M $71.83M
YoY Change -42.5% 15.3%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$9.128M -$14.57M
YoY Change -37.36% 25.37%
Depreciation, Depletion And Amortization $11.00K $5.000K
YoY Change 120.0% -28.57%
Cash From Operating Activities -$11.60M -$11.43M
YoY Change 1.46% 20.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $23.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$210.0K $3.880M
YoY Change -105.41% -49.94%
Cash From Investing Activities -$210.0K $3.854M
YoY Change -105.45% -50.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.410M 42.81M
YoY Change -80.36% -6656.2%
NET CHANGE
Cash From Operating Activities -11.60M -11.43M
Cash From Investing Activities -210.0K 3.854M
Cash From Financing Activities 8.410M 42.81M
Net Change In Cash -3.400M 35.23M
YoY Change -109.65% -1577.27%
FREE CASH FLOW
Cash From Operating Activities -$11.60M -$11.43M
Capital Expenditures $0.00 $23.00K
Free Cash Flow -$11.60M -$11.46M
YoY Change 1.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1709000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15919000
CY2015Q1 us-gaap Assets
Assets
41302000
CY2015Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
6881000
CY2014Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
599000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1988000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1306000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
89000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4937000
CY2015Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3632000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1964000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11433000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7942000
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12303000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7730000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16180000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-212000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3854000
CY2015Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1642000
CY2014Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2261000
CY2014Q1 snss Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
40022000
CY2015Q1 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
10011000
CY2014Q1 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
4726000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3418000
CY2015Q1 us-gaap Notes Payable Current
NotesPayableCurrent
713000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67641000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56313000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
259000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-68000
CY2015Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-268000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8974000
CY2014Q1 us-gaap Interest Expense
InterestExpense
547000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5052000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-14573000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9126000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14566000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1056000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
58000
CY2015Q1 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-887000
CY2014Q1 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1113000
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1258000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-848000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2121000
CY2015Q1 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
2225000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1029000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2781000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
536499000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-522697000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
13802000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41302000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
16793000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44246000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-531825000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
548616000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
9623000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
10969000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8769000
CY2015Q1 us-gaap Interest Expense
InterestExpense
239000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
CY2015Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
2000
CY2014Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
7000
CY2015Q1 us-gaap Revenues
Revenues
854000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9128000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4512000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7552000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5111000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3417000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000
CY2015Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
44000
CY2014Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
116000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-853000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11601000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30327000
CY2015Q1 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
CY2015Q1 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2015Q1 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2015Q1 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
42000
CY2014Q1 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
325000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8411000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
42812000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3402000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
35233000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15121000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50354000
CY2015Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
100000
CY2015Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2015Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39800000
CY2015Q1 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2015Q1 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2015Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015Q1 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
700000
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting. </p></div>
CY2014Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
0
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22547000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28458000
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
27600000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
27594000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30334000
CY2015Q1 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
6585000
CY2015Q1 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
21015000
CY2015Q1 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
6000
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6585000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2015Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P6M
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P9M18D
CY2014Q4 snss Cash Equivalents Amortized Cost
CashEquivalentsAmortizedCost
9532000
CY2014Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
20802000
CY2015Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.934
CY2014Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9532000
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.449
CY2015Q1 snss Common Stock Fair Value
CommonStockFairValue
2.45
CY2014Q4 snss Common Stock Fair Value
CommonStockFairValue
2.55
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2015Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.001
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.002
CY2015Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2015Q1 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
1.24
CY2014Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
1.21
CY2015Q1 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
2920000
CY2014Q4 snss Shares Underlying Outstanding Warrants
SharesUnderlyingOutstandingWarrants
2920000
CY2011Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2015Q1 snss Number Of Tranches For Maximum Borrowing
NumberOfTranchesForMaximumBorrowing
2
CY2015Q1 snss Line Of Credit Facility Number Of Installments
LineOfCreditFacilityNumberOfInstallments
32
CY2015Q1 snss Line Of Credit Facility Final Payment
LineOfCreditFacilityFinalPayment
937500
CY2015Q1 snss Debt Instrument Interest Only Period Start Date
DebtInstrumentInterestOnlyPeriodStartDate
2015-03-01
CY2015Q1 snss Debt Instrument Interest Only Period End Date
DebtInstrumentInterestOnlyPeriodEndDate
2016-02-01
CY2015Q1 snss Number Of Remaining Principal Payments
NumberOfRemainingPrincipalPayments
8
CY2015Q1 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2016-10-01
CY2015Q1 snss Line Of Credit Facility Final Payment
LineOfCreditFacilityFinalPayment
1162500
CY2015Q1 snss Prepayment Penalty Expiration Date
PrepaymentPenaltyExpirationDate
2016-02-29
CY2015Q1 snss Percentage Of Penalty For Prepaying Loan Before Maturity
PercentageOfPenaltyForPrepayingLoanBeforeMaturity
0.02
CY2015Q1 snss Warrants Expiration Term
WarrantsExpirationTerm
P5Y
CY2015Q1 snss Number Of Common Stock Warrants Issued
NumberOfCommonStockWarrantsIssued
61467
CY2015Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
2.22
CY2015Q1 snss Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
100000
CY2015Q1 us-gaap Notes Payable
NotesPayable
7594000

Files In Submission

Name View Source Status
0001564590-15-003315-index-headers.html Edgar Link pending
0001564590-15-003315-index.html Edgar Link pending
0001564590-15-003315.txt Edgar Link pending
0001564590-15-003315-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201505052026436591931.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20150331.htm Edgar Link pending
snss-20150331.xml Edgar Link completed
snss-20150331.xsd Edgar Link pending
snss-20150331_cal.xml Edgar Link unprocessable
snss-20150331_def.xml Edgar Link unprocessable
snss-20150331_lab.xml Edgar Link unprocessable
snss-20150331_pre.xml Edgar Link unprocessable
snss-ex311_201503316.htm Edgar Link pending
snss-ex312_201503317.htm Edgar Link pending
snss-ex321_201503318.htm Edgar Link pending